在人类冠状动脉血管平滑肌肉细胞中,C-反应蛋白诱导了亡
Florian Blaschke1, Dennis Bruemmer, Fen Yin
1Division of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Circulation
|July 28, 2004
概括
在人类冠状动脉血管光滑肌细胞 (VSMCs) 中,C-反应蛋白 (CRP) 通过上调 GADD153 基因,触发编程细胞死亡 (细胞亡). 这一发现揭示了动脉样硬化发展的新机制,并提出了潜在的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 细胞病理学细胞病理学
背景情况:
- C-反应蛋白 (CRP) 是冠状动脉事件的预测因子,可能直接影响动脉样硬化进展.
- 血管光滑肌细胞 (VSMC) 积累和亡对于动脉病变的发展和斑块脆弱性至关重要.
研究的目的:
- 研究CRP在VSMC亡中的作用.
- 在人类冠状动脉VSMC中识别受CRP调节的基因.
- 为了阐明CRP诱导的VSMC亡的机制.
主要方法:
- 用DNA微阵列分析识别CRP调节的基因.
- 北方斑点分析以确认基因表达.
- 小干扰RNA (siRNA) 准GADD153.3,以成为目标.
- 免疫组织化学评估在人类冠状动脉病变中的GADD153局部化.
主要成果:
- 在人类冠状动脉VSMC中,CRP会诱导卡斯巴酶介导的亡.
- CRP显著上调增长停止和DNA损伤诱导的153 (GADD153) 基因的mRNA表达.
- 通过mRNA稳定,CRP主要通过转录后水平调节GADD153mRNA.
- 用siRNA准GADD153可以减少CRP诱导的VSMC亡.
- 在人类冠状动脉病变中,GADD153与亡性VSMCs同位.
结论:
- GADD153是人体VSMC中的CRP调节基因,在CRP诱导的亡中起因作用.
- 向CRP为动脉样硬化提供了一个潜在的新疗法策略.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...